TARIX ORPHAN
Tarix Orphan is a private biopharmaceutical company headquartered in Cambridge, MA. Tarix Orphan is developing TXA127 for rare neuromuscular and connective tissue diseases. TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 has been effective in animal models of Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy MDC1A, Marfan syndrome, and Dystrophic Epidermolysis Bullosa (DEB). Tarix Orphan has broad IP protection for TXA127 and Orphan Drug Designations (ODDs) have been granted for DMD LGMD and DEB in the U.S.,
TARIX ORPHAN
Website Url:
http://www.tarixorphan.com
Status:
Active
Contact:
+1.617.827.6824
Email Addresses:
[email protected]
Technology used in webpage:
Euro Nginx Pound Sterling Japanese Yen Baidu Analytics Energy Group Hosting
Similar Organizations
Mentrik Biotech
Mentrik Biotech, LLC is a private biopharmaceutical company
Spriaso
Spriaso is a biopharmaceutical company.
Yuma Therapeutics
Yuma Therapeutics is a private biopharmaceutical company.
Current Advisors List
Current Employees Featured
Official Site Inspections
http://www.tarixorphan.com
- Host name: 104.201.36.70
- IP address: 104.201.36.70
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tarix Orphan"
Tarix Orphan - Crunchbase Company Profile & Funding
Tarix Orphan is a private biopharmaceutical company headquartered in Cambridge, MA. Tarix Orphan is developing TXA127 for rare neuromuscular and connective tissue diseases. …See details»
Tarix Orphan, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tarix Orphan, LLC of Cambridge, MA. Get the latest business insights from Dun & Bradstreet. Tarix Orphan, …See details»
Tarix Orphan - 2025 Company Profile & Competitors - Tracxn
Tarix Orphan is developing therapeutics for rare neuromuscular and connective tissue diseases. Its lead product TXA127 is a pharmaceutical formulation of the naturally occurring peptide, …See details»
Tarix Orphan, LLC in Cambridge, MA - (617) 827-6824 - Company …
Tarix Orphan, LLC is in the Biotechnical Research, Commercial business. View competitors, revenue, employees, website and phone number.See details»
Tarix Orphan LLC - Drug pipelines, Patents, Clinical trials - Synapse
100 Clinical Results associated with Tarix Orphan LLC. Login to view more data. 0 Patents (Medical) associated with Tarix Orphan LLC. Login to view more data. ... The statistics for …See details»
Tarix Orphan LLC:Company Profile & Technical …
Tarix Orphan LLC is a company that provides Medicine, Immunosuppressive drug, Connective tissue disease and more. Tarix Orphan LLC is headquartered in United States Massachusetts. …See details»
Tarix Orphan Reviews | Read Client Reviews of Tarix Orphan.
Read reviews of Tarix Orphan. Write and share your personal story. Your experience will help others make the right buying decision. Trustburn. Categories Log in For business. Search. …See details»
Tarix Orphan - VentureRadar
BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications.See details»
Review of Tarix Orphan | I recently came across this orphan …
I recently came across this orphan support organization and I am truly impressed by their work. The team at Tarix Orphan is doing an amazing job in empowering orphaned children. The …See details»
Tarix Orphan - Crunchbase
Tarix Orphan LLC is a private biopharmaceutical company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
Tarix Orphan LLC Company Profile, Financial and Strategic
DigitGaps report on Tarix Orphan LLC delivers a detailed in-depth and comprehensive insights of the company, its history, corporate strategy, its businesses and structures, and company …See details»
Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential ...
Feb 17, 2016 Tarix Orphan LLC is a private biopharmaceutical company focused on the development of TXA127, a pharmaceutical formulation of the naturally occurring peptide …See details»
Tarix Orphan Receives Orphan Drug Status for TXA127 for Genetic …
Sep 7, 2016 About Tarix Orphan Tarix Orphan LLC is a private biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases. …See details»
Tarix Orphan LLC - Drug pipelines, Patents, Clinical trials - Synapse
Explore Tarix Orphan LLC with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Nervous System Diseases, Endocrinology and Metabolic Disease, Immune System …See details»
Tarix Orphan - Tech Stack, Apps, Patents & Trademarks
Tarix Orphan LLC is a private biopharmaceutical company. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
Tarix Orphan LLC (Tarix Orphan LLC) - 药物管线_专利_临床试验_投 …
May 1, 2023 了解Tarix Orphan LLC (Tarix Orphan LLC)公司的药物管线，治疗领域，技术平台，以及它的，疾病领域:内分泌与代谢疾病，免疫系统疾病，神经系统疾病，技术平台:合成多 …See details»
Tarix Orphan Granted Orphan Drug Status by the EMA for TXA127 …
Jun 12, 2017 Clare Robinson, Head of Research at DEBRA International, a leading EB patient organization, responded to the announcement, "People with EB frequently face disabling …See details»
Tarix Orphan - Contacts, Employees, Board Members ... - Crunchbase
Organization. Tarix Orphan . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. ... Tarix Orphan has 2 current …See details»
LAMA2 Muscular Dystrophy Drug Candidate TXA127 Is Granted …
Feb 18, 2016 “This is the third U.S. Orphan Drug designation granted to TXA127 for muscular dystrophies, with previously received designations for Duchenne muscular dystrophy (DMD), …See details»
Tarix Granted Orphan Drug Status For TXA127
Feb 17, 2016 <p>Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, …See details»